Clinical significance of plasma pTau217 in the care of patients in German outpatient memory clinics

Clinical significance of plasma pTau217 in the care of patients in German outpatient memory clinics - Plasma pTau217 - DNG

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033361

Enrollment

600

Registered

2025-01-28

Start date

2026-08-01

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F06.7 F00.1 F00.0 F03

Interventions

Group 1: Participants with AD pathology (A+T+) - Measurement of AD biomarkers in plasma and cerebrospinal fluid. Samples are derived from the local biobanks of the participating centres. - Use of bas

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosis: MCI or dementia Biomarker status A+T+, A+T- oder A-T-

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
1. Investigation of the sensitivity and specificity of plasma pTau217 for Alzheimer's pathology defined according to the local reference standard (CSF or PET).	—

Secondary

Measure	Time frame
2. Additional measurement of pTau217 in cerebrospinal fluid. Here, the extent to which plasma pTau217 corresponds with CSF pTau217 in a multicenter memory outpatient sample is tested. 3. Additional central measurement of Aß42/40 and pTau217 (other measurement techniques) in plasma and CSF in Germany for central verification of CSF diagnostics and for comparative analysis of plasma biomarkers in relation to CSF biomarkers in the multicenter sample.	—

Measure

Time frame

2. Additional measurement of pTau217 in cerebrospinal fluid. Here, the extent to which plasma pTau217 corresponds with CSF pTau217 in a multicenter memory outpatient sample is tested. 3. Additional central measurement of Aß42/40 and pTau217 (other measurement techniques) in plasma and CSF in Germany for central verification of CSF diagnostics and for comparative analysis of plasma biomarkers in relation to CSF biomarkers in the multicenter sample.

—

Countries

Germany

Contacts

Public ContactMichelle Gerards

Zentrum für Gedächtnisstörung, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Uniklinik Köln

michelle.gerards@uk-koeln.de02214780

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026